FastWave Medical has announced the issuance of its third utility patent by the US Patent and Trademark Office (USPTO).
The newly granted patent supports the differentiated design of FastWave’s next-generation intravascular lithotripsy (IVL) system, which aims to address challenges associated with treating calcified arteries in patients with occlusive vascular disease—a condition affecting millions of people worldwide and the leading cause of cardiovascular morbidity and mortality.
Farouc Jaffer (Massachusetts General Hospital and Harvard Medical School, Boston, USA) and one of FastWave Medical’s physician advisors, expressed enthusiasm for the patent, stating: “The issuance of FastWave’s third utility patent is a testament to the phenomenal work being done by their experienced team. This milestone further validates the strength and novelty of the company’s technology, which has the potential to positively impact patient outcomes.”
Jaffer was one of several physician advisors recently appointed by the company, among a list that includes: Amir Kaki (St John’s Medical Center, Detroit, USA), Kathleen Kearney (University of Washington, Seattle, USA), Arthur Lee (The Cardiac & Vascular Institute, Gainesville, USA), Miguel Montero-Baker (HOPE Vascular and Podiatry, Houston, USA), William Nicholson (Emory Healthcare, Atlanta, USA), Peter Schneider (University of California San Francisco, San Francisco, USA), and Venkatesh Ramaiah (Pulse Cardiovascular and HonorHealth, Scottsdale, USA).
Co-founder and CEO of FastWave Medical, Scott Nelson, said: “We are thrilled to receive our third utility patent, which further validates the ingenuity of our IVL systems. This milestone underscores our dedication to empowering physicians with innovative tools that enhance patient care and improve clinical outcomes.”
